Lomocare 40mg Injection

Enoxaparin

Uses of Lomocare 40mg Injection

  • Treat and prevent blood clot

Introduction to Lomocare 40mg Injection

Lomocare 40mg injection is an anticoagulant drug in the low molecular weight heparin (LMWH) category, containing the active ingredient enoxaparin. It is used to treat severe blood clots. This drug also prevents the occurrence of deep vein thrombosis in abdominal surgery, hip replacement surgery, knee replacement surgery, and in people with severe movement restrictions. This injection prevents further heart complications in patients with unstable angina and non-Q wave myocardial infarction.

This injection is contraindicated for patients with active bleeding, hypersensitivity, and a history of heparin-induced thrombocytopenia. Before taking the Lomocare 40mg injection , tell your physician if you are allergic to enoxaparin sodium, heparin, benzyl alcohol, or pork products. Your healthcare provider will regularly monitor you for signs of bleeding. Inform your healthcare practitioner if you are diagnosed with kidney problems. Tell your physician if you suspect pregnancy, breastfeeding, or planning to have a baby. It is probably unsafe during pregnancy as it may increase the chance of thrombosis in pregnant women and harm them and their foetus. Consult your doctor for more advice.

Therapeutic Effects of Lomocare 40mg Injection

Lomocare 40mg injection binds to the antithrombin to form a complex. Antithrombin is a protein that blocks the formation of abnormal blood clots. This drug mainly prevents the activation of factor Xa, eventually preventing clot formation.


Interaction of Lomocare 40mg Injection with other drugs

Inform your physician about any prescribed medications, over-the-counter medicines, and nutritional or vitamin supplements you have taken before the treatment. Certain medications may interact with Lomocare 40mg injection and cause undesirable side effects.


More Information about Lomocare 40mg Injection

  • Store Lomocare 40mg injection  below (30°C).
  • Do not freeze.

How to consume Lomocare 40mg Injection

Lomocare 40mg injection can be self administered, the first dose will be demonstrated by your doctor. Your doctor will decide the dose, route of administration, and frequency based on your disease condition and other factors.


Safety Advices for Lomocare 40mg Injection

 

Pregnancy

Report to your doctor if you are pregnant, suspecting, or planning for the pregnancy before starting the treatment with Lomocare 40mg injection.

 

Breast Feeding

If you are breastfeeding, it is highly advised to consult your doctor before administering an Lomocare 40mg injection.

 

Lungs

It is unknown whether Lomocare 40mg injection is safe for patients with lung problems. Consult your doctor if you have lung disease before starting the treatment.

 

Liver

Inform your doctor if you have liver disease because Lomocare 40mg injection should be used cautiously with a liver condition.

 

Alcohol

It is unknown whether consuming alcohol while taking an Lomocare 40mg injection is safe. Please speak with your physician.

 

Driving

It is safe to travel, drive vehicles, or operate heavy machinery after administering Lomocare 40mg injection. The medicine does not impair any alertness and coordination.


Side Effects of Lomocare 40mg Injection

Side Effects are unwanted symptoms caused by medicines. Although all medicines cause side effects, not everyone gets them.

Serious

  • Severe allergic reactions (swelling of lips, tongue, or throat, difficulty breathing, or swallowing)
  • Too much bleeding (weakness, being pale, dizziness with headache, or unexplained swelling)
  • Blockage of blood vessels (pain, redness, or swelling in the legs, or coughing up blood)
  • Rash of dark red spots under the skin

Common

  • Bleeding
  • Bruising more easily
  • Low blood cell counts
  • Headache
  • Itchy red skin
  • Pink patches on the skin

Brand

Gufic Bioscience LTD

Reviews

There are no reviews yet.

Be the first to review “Lomocare 40mg Injection”

Your email address will not be published. Required fields are marked *

Top